HeinleJWDalessioSJanickiP, et al.Insights into the voltage-gated sodium channel, NaV1.8, and its role in visceral pain perception. Vol. 15, Frontiers in Pharmacology. Frontiers Media SA, 2024.
2.
OsteenJDImmaniSTapleyTL, et al.Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain Ther2025; 14(2): 655–674.
3.
BertochTD’AunnoDMcCounJ, et al.Suzetrigine, a non-opioid NaV1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials. Anesthesiology2025; 142(6): 1085–1099.
4.
McCounJWinklePSolankiD, et al.Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a phase 3 single-arm study for surgical or non-surgical acute pain. J Pain Res2025; 18: 1569–1576.
